3rd Annual Hematologic Malignancies Symposium

 

3rd Annual Hematologic Malignancies Symposium
A

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Benefit? What Is the Role of MRD? Is Sorafenib a Good Maintenance Choice?

By 3rd Annual Hematologic Malignancies Symposium FEATURING Alexander Perl
By 3rd Annual Hematologic Malignancies Symposium FEATURING Alexander Perl
0 views
April 8, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Videos
26:33
3rd Annual Hematologic Malignancies Symposium

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Ben…

Feat. A. Perl
07:34
3rd Annual Hematologic Malignancies Symposium

2021 Updates on FLT3m R/R AML: What Is the Current Standard of Care?…

Feat. A. Perl
15:35
3rd Annual Hematologic Malignancies Symposium

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

Feat. G. Roboz
22:10
3rd Annual Hematologic Malignancies Symposium

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Th…

Feat. C. DiNardo
26:23
3rd Annual Hematologic Malignancies Symposium

HMA Resistance & Treatment After HMT Failure in MDS: Aza vs. CCR…

Feat. H. Carraway
15:41
3rd Annual Hematologic Malignancies Symposium

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy…

Feat. A. Wei